Gyre Therapeutics Changes Fiscal Year End
Ticker: GYRE · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1124105
| Field | Detail |
|---|---|
| Company | Gyre Therapeutics, Inc. (GYRE) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-actions, reporting-change
TL;DR
Gyre Therapeutics is changing its fiscal year end to Dec 31st, effective June 12, 2024.
AI Summary
Gyre Therapeutics, Inc. (formerly Catalyst Biosciences, Inc.) filed an 8-K on June 17, 2024, reporting a change in its fiscal year end to December 31st, effective June 12, 2024. This filing also indicates the submission of matters to a vote of security holders and includes financial statements and exhibits.
Why It Matters
A change in fiscal year end can impact reporting schedules and financial analysis timelines for investors.
Risk Assessment
Risk Level: low — This filing primarily concerns administrative and reporting changes, not significant operational or financial events.
Key Players & Entities
- Gyre Therapeutics, Inc. (company) — Registrant
- Catalyst Biosciences, Inc. (company) — Former Company Name
- Targacept Inc (company) — Former Company Name
- June 12, 2024 (date) — Effective date of fiscal year change
- June 17, 2024 (date) — Filing date of the 8-K
- December 31 (date) — New fiscal year end
FAQ
What is the new fiscal year end for Gyre Therapeutics, Inc.?
The new fiscal year end for Gyre Therapeutics, Inc. is December 31st.
When was the change in fiscal year end effective?
The change in fiscal year end was effective as of June 12, 2024.
What was Gyre Therapeutics, Inc. formerly known as?
Gyre Therapeutics, Inc. was formerly known as Catalyst Biosciences, Inc.
What is the filing date of this 8-K report?
This 8-K report was filed on June 17, 2024.
Besides the fiscal year change, what other items are reported in this 8-K?
This 8-K also reports the submission of matters to a vote of security holders and includes financial statements and exhibits.
Filing Stats: 840 words · 3 min read · ~3 pages · Grade level 12.3 · Accepted 2024-06-17 16:30:28
Filing Documents
- ef20031213_8k.htm (8-K) — 48KB
- ef20031213_ex3-1.htm (EX-3.1) — 8KB
- 0001140361-24-030348.txt ( ) — 197KB
- gyre-20240612.xsd (EX-101.SCH) — 4KB
- gyre-20240612_lab.xml (EX-101.LAB) — 22KB
- gyre-20240612_pre.xml (EX-101.PRE) — 16KB
- ef20031213_8k_htm.xml (XML) — 4KB
03
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. At the Annual Meeting, the Company's stockholders approved an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), to extend the exculpation provisions contained therein to certain officers and make certain other changes (the "Amendment"). On June 14, 2024, the Company filed a Certificate of Amendment (the "Certificate of Amendment") to the Certificate of Incorporation with the Secretary of State of the The foregoing description of the Certificate of Amendment does not purport to be complete and is subject to and qualified in its entirety by reference to the Certificate of Amendment, a copy of which is attached hereto as Exhibit 3.1 and incorporated herein by reference.
07
Item 5.07. Submission of Matters to a Vote of Security Holders. At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved. The proposals are described in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 29, 2024. The final voting results are set forth below. Proposal 1: Election of Directors The following Class III director nominees were elected to serve until the 2027 Annual Meeting of Stockholders based upon the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Thomas Eastling 68,900,969 211,021 331,358 Renate Parry, Ph.D. 69,107,060 4,930 331,358 Rodney Nussbaum 69,107,047 4,943 331,358 Proposal 2: Non-Binding Advisory Vote on Executive Compensation The compensation of the Company's named executive officers was approved, on a non-binding, advisory basis, as follows: Votes For Votes Against Abstentions Broker Non-Votes 69,101,285 7,487 3,218 331,358 Proposal 3: Ratification of Independent Auditor The appointment of Grant Thornton Zhitong Certified Public Accountants LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024 was ratified as follows: Votes For Votes Against Abstentions Broker Non-Votes 69,435,580 7,601 167 0 2 Proposal 4: Approval of the Amendment to the Certificate of Incorporation An amendment of the Company's Certificate of Incorporation to extend the exculpation provisions contained therein to certain officers and make certain other changes was approved as follows: Votes For Votes Against Abstentions Broker Non-Votes 68,971,890 136,936 3,164 331,358
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . The following exhibits are being furnished herewith: Exhibit Number Exhibit Title or Description 3.1 Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Gyre Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GYRE THERAPEUTICS, INC. Date: June 17, 2024 By: /s/ Han Ying, Ph.D. Name: Han Ying, Ph.D. Title: Chief Executive Officer 4